USA flag logo/image

An Official Website of the United States Government

Company Information:

Company Name: MOLECULAR INSIGHT PHARMACEUTICALS, INC.
City: CAMBRIDGE
State: MA
Zip+4: 02142-
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
Website URL: N/A
Phone: N/A

Award Totals:

Program/Phase Award Amount ($) Number of Awards
SBIR Phase I $3,092,969.00 14
SBIR Phase II $8,391,507.00 6
STTR Phase I $677,184.00 2

Award List:

Halopiperidines for imaging of monoamine transporters

Award Year / Program / Phase: 2003 / SBIR / Phase I
Agency: HHS
Principal Investigator: Miles P. Smith
Award Amount: $190,643.00
Abstract:
DESCRIPTION (provided by applicant): The monoamine transporters are important targets for therapy, diagnosis and monitoring of a number of CNS disease states. It is expected that imaging agents that exhibit high affinity and selectivity for the dopamine transporter (DAT) would fulfill a number of… More

Labeled inhibitors for angiotensin converting enzyme

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: John W. Babich
Award Amount: $337,713.00
Abstract:
DESCRIPTION (provided by applicant): Despite the trend of decreasing death rates attributable to ischemic heart disease and stroke, the prevalence of congestive heart failure and the resultant death rates in the United States have almost tripled over the past three decades. Congestive heart… More

Novel Ether Containing Ligand Complexes: Cardiac Imaging

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Kevin P. Maresca
Award Amount: $159,525.00
Abstract:
DESCRIPTION (provided by applicant): There remains a clinical need for myocardial perfusion tracers that more accurately reflect cardiac blood flow over a wide range of flow rates while simultaneously demonstrating a reduced accumulation and/or rapid clearance from the tissues adjacent to the… More

Norepinephrine Transporters: Targets for ADHD

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: Frank I. Tarazi
Award Amount: $301,412.00
Abstract:
DESCRIPTION (provided by applicant): Attention-deficit hyperactivity disorder (ADHD) is a complex developmental behavioral and cognitive disorder characterized by hyperactivity, inattention and impulsivity. The most widely prescribed pharmacological treatment for ADHD patients has been… More

Novel glutamate conjugates for radiotargeting PSMA

Award Year / Program / Phase: 2004 / SBIR / Phase I
Agency: HHS
Principal Investigator: John W. Babich
Award Amount: $327,235.00
Abstract:
DESCRIPTION (provided by applicant): The development of novel approaches for radioimmunoimaging and radioimmunotherapy is driven by the high incidence and mortality rate associated with prostate cancer in the United States. One strategy to diagnostic and prognostic markers exploits… More

An Instant Kit for 2-[18F]Fluoro-2-deoxyglucose (FDG)

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: John W. Babich
Award Amount: $130,387.00
Abstract:
DESCRIPTION (provided by applicant): Since the development of the high yield nucleophilic fluorination reaction by Hamacher et al. and the development of commercially available precursors for one or two step synthesis of F-18 labeled targeted molecules, a large number of molecular imaging probes… More

High sensitivity and low toxicity radiopharmaceuticals

Award Year / Program / Phase: 2005 / SBIR / Phase I
Agency: HHS
Principal Investigator: James F. Kronauge
Award Amount: $147,491.00
Abstract:
DESCRIPTION (provided by applicant): True molecular imaging is generated by compounds that target specific bio-molecules or molecular pathways. We propose to develop a solid-phase radiolabeling process that will lead to higher sensitivity radiopharmaceuticals with a higher margin of safety… More

Size-Dependent Uptake of Tc(I)-Labeled RGD Analogs

Award Year / Program / Phase: 2005 / STTR / Phase I
Agency: HHS
Research Institution: UNIVERSITY OF CALIFORNIA SAN DIEGO
Principal Investigator: David R. Vera
Award Amount: $299,810.00
RI Contact: N/A
Abstract:
DESCRIPTION (provided by applicant): Anti-angiogenic therapy is currently one of the most active fields in cancer research. There are four basic approaches to limiting angiogenesis: blocking growth factors, inhibiting matrix proteases, directly targeting endothelial cells, and upregulating… More

Developing Nanodosing of Iobenguane I 131 for Radiotherapy

Award Year / Program / Phase: 2006 / SBIR / Phase II
Agency: HHS
Principal Investigator: James F. Kronauge
Award Amount: $925,243.00
Abstract:
DESCRIPTION (provided by applicant): This Phase 2 SBIR is for the development of a drug product identified and demonstrated in the Phase 1 SBIR award (R43CA15120-01). The ultimate goal is to produce, sell and deliver doses of high specific activity iobenguane I 131 for radiotherapy in adults and… More

PEPTIDES FOR IMAGING AND THERAPY USING SAAC AND HTS

Award Year / Program / Phase: 2006 / SBIR / Phase I
Agency: HHS
Principal Investigator: John Babich
Award Amount: $164,108.00

Nanodosing: A path to higher sensitivity and lower toxicity pharmaceuticals

Award Year / Program / Phase: 2007 / SBIR / Phase I
Agency: HHS
Principal Investigator: James F. Kronauge
Award Amount: $130,761.00
Abstract:
DESCRIPTION (provided by applicant): Current availability of iobenguane I 123 is limited to single doses labeled at regional radiopharmacies with variable formulations and specific activities. The objective of this Fast track phase 1/2 SBIR is to produce a nd perform safety testing in humans of a… More

Systemic radiotherapy for metastatic melanomas: Innovation of a novel radiopharma

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator: James F. Kronauge
Award Amount: $331,449.00
Abstract:
DESCRIPTION (provided by applicant): The ultimate goal of this Fast Track Phase I/II SBIR proposal is to develop the novel pharmaceutical agent 131I-MIP-1145, as a molecular targeting radio-therapeutic treatment for metastatic melanoma. Preliminary results with the former lead compound were highly… More

Radiolabeled Inhibitors of Carbonic Anhydrase IX

Award Year / Program / Phase: 2008 / SBIR / Phase I
Agency: HHS
Principal Investigator:
Award Amount: $204,351.00
Abstract:
DESCRIPTION (provided by applicant): The NCI estimates that in 2008 there will be more than 54,000 new cases of renal cell cancer in the United States and that it will claim the lives of more than 13,000 Americans. Overt metastatic disease is present at th e time of diagnosis in 25% of patients,… More

Nanodosing: A path to higher sensitivity and lower toxicity pharmaceuticals

Award Year / Program / Phase: 2008 / SBIR / Phase II
Agency: HHS
Principal Investigator: James F. Kronauge
Award Amount: $981,548.00
Abstract:
DESCRIPTION (provided by applicant): Current availability of iobenguane I 123 is limited to single doses labeled at regional radiopharmacies with variable formulations and specific activities. The objective of this Fast track phase 1/2 SBIR is to produce a nd perform safety testing in humans of a… More

Systemic radiotherapy for metastatic melanomas: Innovation of a novel radiopharma

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: James F. Kronauge
Award Amount: $1,634,480.00
Abstract:
DESCRIPTION (provided by applicant): The ultimate goal of this Fast Track Phase I/II SBIR proposal is to develop the novel pharmaceutical agent 131I-MIP-1145, as a molecular targeting radio-therapeutic treatment for metastatic melanoma. Preliminary results with the former lead compound were highly… More

Development of a Molecular Targeting Agent for PSMA to Diagnose Metastatic Prosta

Award Year / Program / Phase: 2009 / SBIR / Phase II
Agency: HHS
Principal Investigator: James F. Kronauge
Award Amount: $1,617,727.00
Abstract:
DESCRIPTION (provided by applicant): Abstract There is presently no effective therapy for relapsing, metastatic, androgen-independent prostate cancer and the most effective treatment occurs with early and appropriate intervention. Blood PSA screening and digital rectal exams can detect early warning… More

Early Clinical Testing for Melanin Targeting Radio-therapeutic agent in melanoma

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: John W. Babich
Award Amount: $223,985.00
Abstract:
DESCRIPTION (provided by applicant): The ultimate goal of this Fast Track Phase I/II SBIR proposal is to perform the clinical assessment of a novel pharmaceutical agent, ioflubenzamide I-131, to evaluate its potential as a molecular targeting radio-the rapeutic treatment for metastatic melanoma.… More

Targeting Tumor Microenvironment with Radiolabeled Inhibitors of Seprase (FAPalph

Award Year / Program / Phase: 2009 / SBIR / Phase I
Agency: HHS
Principal Investigator: John L. Joyal
Award Amount: $180,916.00
Abstract:
DESCRIPTION (provided by applicant): The American Cancer Society estimates that in 2008 there will be more than 1.4 million new cases of cancer in the United States and that it will claim the lives of more than 500,000 Americans. The vast majority of t hese cases will be solid tumors, and overt… More

Early Clinical Testing for Melanin Targeting Radio-therapeutic agent in melanoma

Award Year / Program / Phase: 2010 / SBIR / Phase II
Agency: HHS
Principal Investigator: John W. Babich
Award Amount: $1,296,834.00
Abstract:
DESCRIPTION (provided by applicant): The ultimate goal of this Fast Track Phase I/II SBIR proposal is to perform the clinical assessment of a novel pharmaceutical agent, ioflubenzamide I-131, to evaluate its potential as a molecular targeting radio-the rapeutic treatment for metastatic melanoma.… More

Development of a kit based PET molecular imaging agent: edotreotide Ga 68 for so

Award Year / Program / Phase: 2010 / SBIR / Phase I
Agency: HHS
Principal Investigator: James F. Kronauge
Award Amount: $262,993.00
Abstract:
DESCRIPTION (provided by applicant): Synthetic peptides targeted to Somatostatin receptors (SSTR) were developed almost 30 years ago by Novartis to inhibit the effects of endogenous growth factors on malignant tissues. The radio-therapeutic version has bee n licensed to Molecular Insight and the… More

A kit based PET agent: edotreotide Ga 68 for clinical imaging of somatostatin rec

Award Year / Program / Phase: 2012 / SBIR / Phase II
Agency: HHS
Principal Investigator: James F. Kronauge – 617-492-5554
Award Amount: $1,935,675.00
Abstract:
DESCRIPTION (provided by applicant): A kit based PET agent: edotreotide Ga 68 for clinical imaging of somatostatin receptor expressing tissue. Synthetic peptides targeted to Somatostatin receptors (SSTR) were developed almost 30 years ago by Novartis to inhibit the effects of endogenous growth… More